Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma

This open-label phase 2 study (CONTRALTO) assessed the safety and efficacy of BCL-2 inhibitor venetoclax (VEN) plus rituximab (R), and VEN plus bendamustine (B) and R, vs B + R (BR) alone in relapsed/refractory (R/R) follicular lymphoma. Patients in the chemotherapy-free arm (arm A: VEN + R) receive...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Blood
Huvudupphovsmän: Zinzani, Pier Luigi, Flinn, Ian W., Yuen, Sam L. S., Topp, Max S., Rusconi, Chiara, Fleury, Isabelle, Le Dû, Katell, Arthur, Christopher, Pro, Barbara, Gritti, Giuseppe, Crump, Michael, Petrich, Adam, Samineni, Divya, Sinha, Arijit, Punnoose, Elizabeth A., Szafer-Glusman, Edith, Spielewoy, Nathalie, Mobasher, Mehrdad, Humphrey, Kathryn, Kornacker, Martin, Hiddemann, Wolfgang
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Society of Hematology 2020
Ämnen:
Clinical Trials and Observations
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7735159/
https://ncbi.nlm.nih.gov/pubmed/32785666
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020005588
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk